Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.18−0.19 (-5.64%)
Close on Nov 16, 2026Market cap $222.90MP/E –Yield 0.00%
Bicycle Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Bicycle Therapeutics's total debt was $30.91M at Jun 30, 2024. For fiscal 2023 it was $30.70M, up 1.3% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $30.70M | +1.3% |
| FY2022 | Dec 31, 2022 | $30.32M | +1.5% |
| FY2021 | Dec 31, 2021 | $29.87M | +105.9% |
| FY2020 | Dec 31, 2020 | $14.51M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2024 | Jun 30, 2024 | $30.91M | +1.3% |
| Q1 FY2024 | Mar 31, 2024 | $30.80M | +1.3% |
| Q4 FY2023 | Dec 31, 2023 | $30.70M | +1.3% |
| Q3 FY2023 | Sep 30, 2023 | $30.60M | +1.2% |
| Q2 FY2023 | Jun 30, 2023 | $30.51M | +1.2% |
| Q1 FY2023 | Mar 31, 2023 | $30.42M | +1.4% |
| Q4 FY2022 | Dec 31, 2022 | $30.32M | +1.5% |
| Q3 FY2022 | Sep 30, 2022 | $30.23M | +1.6% |
| Q2 FY2022 | Jun 30, 2022 | $30.14M | +1.7% |
| Q1 FY2022 | Mar 31, 2022 | $30.01M | +1.7% |
| Q4 FY2021 | Dec 31, 2021 | $29.87M | +105.9% |
| Q3 FY2021 | Sep 30, 2021 | $29.75M | +106.2% |
| Q2 FY2021 | Jun 30, 2021 | $29.63M | – |
| Q1 FY2021 | Mar 31, 2021 | $29.50M | – |
| Q4 FY2020 | Dec 31, 2020 | $14.51M | – |
| Q3 FY2020 | Sep 30, 2020 | $14.43M | – |
See a number that looks wrong?